Cargando…
Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019
Concerning development of medicinal products, children belong to a so-called “special population” for which additional legislation applies: Regulation (EC) No 1901/2006 on medicinal products for paediatric use sets up a system of requirements, rewards and incentives to ensure that medicinal products...
Autores principales: | Mahler, V., Mentzer, D., Bonertz, A., Muraro, A., Eigenmann, P., Bousquet, J., Halken, S., Pfaar, O., Jutel, M., Wahn, U., Vieths, S., Kaul, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325268/ https://www.ncbi.nlm.nih.gov/pubmed/32612805 http://dx.doi.org/10.1186/s13601-020-00327-w |
Ejemplares similares
-
Allergen Immunotherapy (AIT): a prototype of Precision Medicine
por: Canonica, GW, et al.
Publicado: (2015) -
AIT (allergen immunotherapy): a model for the “precision medicine”
por: Passalacqua, Giovanni, et al.
Publicado: (2015) -
Physicians' attitude to allergen immunotherapy (AIT) prescription: an Italian survey
por: Modiano, Ambra
Publicado: (2015) -
Vitamin D Role in Childhood Mite Allergy and Allergen Immunotherapy (AIT)
por: Petrarca, Claudia, et al.
Publicado: (2023) -
Real world evidence of long-term benefits from allergen-specific immunotherapy (AIT)
por: Scadding, Guy
Publicado: (2021)